ACTG084, 1992.
Study characteristics | ||
Methods | Single arm trial | |
Participants | 42 (after dAmB induction) participants enrolled; 1 excluded after enrolment as diagnosis not confirmed. | |
Interventions | ITRA 200 mg BD for prevention of relapse (maintenance) | |
Outcomes | Relapse (clinical evaluation) Death Follow‐up 109 weeks (range 4–134 weeks) |
|
Age | Mean 33 (range 16–50) years | |
Setting | USA | |
Disease severity | Not stated | |
Notes | 2/42 participants relapsed |